YY

Yuexin Yu

Director at Andera Partners

Paris, Île-de-France

Overview

Work Experience

AP

Andera Partners

  • Director

    2024 - Current

    Amolyt (acquired by AZ), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), Mineralys (MLYS), Artios, Evommune, Tubulis, TargED, JenaValve

  • Investment Director

    2021 - 2024

E

Evommune

  • Board Member

    2024

TB

TargED Biopharmaceuticals

  • Board Observer

    2022

3H

3H Health Investment Management

  • Vice President

    2020 - 2021

    InnoCare (HK.9969, SH.688428), KeyMed (HK.2162), CanSino (HK.6185), EdiGen, RareStone Group, Imperative Care, HeMo Bioengineering

  • Senior Associate

    2018 - 2020

  • Associate

    2016 - 2018

M

Merck

  • Project Manager

    2014 - 2016

    Remicade, Keytruda

b

bioTheranostics

  • Business Development Associate

    2013 - 2013

ME

Merieux Equity Partners

  • Business Analyst

    2012 - 2013

Education

Relevant Websites